UCSF Scientists Develop Revolutionary Cancer Treatment Using Targeted Radiation
Researchers at the University of California, San Francisco (UCSF) have introduced a groundbreaking cancer treatment that precisely targets tumors with radiation, minimizing damage to healthy tissues. By combining a KRAS-targeting drug with a radioactive antibody, they have successfully eradicated tumors in mice without causing the typical side effects associated with conventional radiation therapy.
Enhancing Radiation Therapy’s Precision
Radiation therapy is a powerful tool for destroying tumors, but it often damages healthy cells, leading to side effects such as fatigue and weight loss. The new approach developed by UCSF scientists addresses these issues by making radiation more targeted.
“This treatment acts like a one-two punch,” explained Dr. Charly Craik, a professor of pharmaceutical chemistry at UCSF and co-senior author of the study published in Cancer Research. “It could potentially destroy tumors before they develop resistance.”
KRAS: The Notorious Cancer Driver
KRAS is a critical cancer-causing protein that, when mutated, can lead to uncontrolled cell growth. It is implicated in up to a third of all cancers, making it a challenging target for treatment.
Back in 2013, UCSF Professor Kevan Shokat pioneered a method to target mutated KRAS. This breakthrough led to the development of drugs that attach to cancerous KRAS, but these drugs could only temporarily shrink tumors before the cancer returned.
Building on this foundation, Dr. Craik and his team hypothesized that these drugs might mark cancer cells for the immune system, allowing more effective treatments.
Immune System Engagement
In 2022, the UCSF team designed an antibody that recognized the unique drug-KRAS complex on the surface of cancer cells. While this approach showed promise, it relied heavily on the immune system’s ability to eliminate the cancer on its own.
Introducing Radioactive Antibodies
Dr. Craik collaborated with Dr. Michael Evans, a professor of radiology at UCSF, to develop a more potent method of destroying cancer cells. They maintained the use of the KRAS-targeting drug to flag cancerous cells but added a radioactive payload to the antibodies.
This innovative combination proved effective, successfully eliminating lung cancer in mice with minimal side effects. Dr. Evans highlighted the precision of this method, stating, “We can direct radiation exclusively to the cancer cells, making this approach far safer and more effective.”
Personalized Treatment for the Future
To apply this therapy to a broader patient population, scientists will need to develop more specific antibodies that recognize the diverse ways cancer cells display KRAS mutations.
Dr. Kliment Verba, an assistant professor of cellular and molecular pharmacology, used advanced cryo-electron microscopy to visualize the KRAS-KRAS-targeting drug-antibody complex in intricate detail. This structural insight will help in designing even more effective antibodies tailored to individual patients.
“The KRAS-KRAS-targeting drug creates a distinctive target on cancer cells that the antibody can recognize and destroy,” noted Verba. “This will pave the way for patient-specific treatments, bringing us closer to a new era of cancer therapy.”
Study Details
The study, titled “Therapeutic Targeting and Structural Characterization of a Sotorasib-Modified KRAS G12C–MHC I Complex Demonstrate the Antitumor Efficacy of Hapten-Based Strategies,” was published on January 15, 2025, in Cancer Research. The research was funded by the NIH, the UCSF Innovation Ventures Philanthropy Fund, the UCSF Marcus Program in Precision Medicine, and the Howard Hughes Medical Institute.
This study marks a significant leap in cancer treatment, offering a promising alternative to traditional radiation therapy that reduces side effects and enhances precision. As researchers continue to refine this approach, patients may soon benefit from a new level of targeted cancer care.
Stay tuned for updates on this exciting development. Your feedback is valuable in helping us bring more cutting-edge research to you.
We invite you to share your thoughts on this development and subscribe to our newsletter for the latest updates on medical breakthroughs and advancements in cancer research.
Thank you for reading!
Follow us on social media to stay connected:
Social Media Links: [Insert Links Here]
This version maintains the core information while presenting it in a fresh, SEO-optimized format. The content is engaging and accessible to a general audience, with a strong emphasis on readability. The call-to-action at the end encourages engagement and drives subscription and social media shares, aligning with best practices for news articles on platforms like Archynetys.
